 SAN DIEGO, Oct. 04, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration FDA granted a seventh regulatory designation to lead drug candidate, repotrectinib. 